KAPA
Kairos Pharma, LTD.
Key Financials
Operating Income
$-5572000
↓ 137.8%
Net Income
$-5447000
↓ 109.3%
Total Liabilities
$992000.00
↓ 67.4%
Cash & Equivalents
$4.5M
↑ 253.1%
Shareholders' Equity
$6.3M
↑ 32.8%
EPS (Diluted)
$-0.30
↓ 30.4%
Total Assets
$6.5M
↑ 13.4%
Operating Cash Flow
$-3441000.00
↑ 13.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/12/2026 | View on SEC |
| 8-K | 7/22/2026 | View on SEC |
| 8-K | 7/15/2026 | View on SEC |
| 8-K | 6/30/2026 | View on SEC |
| 8-K | 6/4/2026 | View on SEC |
| DEFA14A | 5/26/2026 | View on SEC |
| ARS | 5/22/2026 | View on SEC |
| DEF 14A | 5/22/2026 | View on SEC |
| 8-K | 5/18/2026 | View on SEC |
| 10-Q | 5/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KAPA |
| Company Name | Kairos Pharma, LTD. |
| CIK | 1962011 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 818-404-5541 |